Robbinsville, NJ, United States of America

Daniel J Coughlin

This inventor holds 19 USPTO granted patents and 3 published patent applications, plus 4 CIPO patents and 1 EPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Cytogen Corporation, Johnson Matthey Public Limited Company, Kempharm, Inc.. Active years: 1989-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel J Coughlin. Retrieved from https://idiyas.com/inventor/daniel-j-coughlin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 19 

% Patents Active = 100.0



Average Co-Inventor Count = 2.8

ph-index = 13

Forward Citations = 908(Granted Patents)


Location History:

  • Plainsboro, NJ (US) (1989 - 1992)
  • Robbinsville, NJ (US) (1990 - 1997)
  • Mullica Hill, NJ (US) (2017 - 2018)
  • Paulsboro, NJ (US) (2018)

Company Filing History:


Years Active: 1989-2018

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Decitabine Purification
Alkylated Aryl Piperazine
Hydrocodone Salts
Metal-Binding Constructs
Bifunctional Chelators
Aminophosphonic Acids
Radiohalogenated Compounds
Antibody Conjugates
Porphyrin Derivatives
Folic Acid Analogs
Isothiocyanate Ligands
19 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Daniel J Coughlin

Introduction

Daniel J Coughlin is a prominent inventor based in Robbinsville, NJ (US), known for his significant contributions to the field of pharmaceuticals. With a total of 19 patents to his name, Coughlin has made remarkable advancements in drug purification and synthesis methods.

Latest Patents

One of Coughlin's latest patents is a method for the purification of decitabine. This innovative process involves mixing crude decitabine with a solvent, such as dimethylacetamide, to create a solution or suspension. The purification process includes adding an anti-solvent, like ethanol, to the mixture, followed by cooling and isolating the solid decitabine. The method aims to achieve a high purity ratio of the β-anomer to the α-anomer of decitabine, ideally at least about 99.9:0.1. Another notable patent involves processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds, which include novel intermediates and methods for their synthesis.

Career Highlights

Coughlin has worked with several reputable companies throughout his career, including Cytogen Corporation and Johnson Matthey Public Limited Company. His work in these organizations has contributed to the development of innovative pharmaceutical solutions.

Collaborations

Coughlin has collaborated with notable colleagues such as Benjamin A Belinka, Jr and Vernon L Alvarez, further enhancing his contributions to the field.

Conclusion

Daniel J Coughlin's innovative work in drug purification and synthesis has made a significant impact in the pharmaceutical industry. His numerous patents reflect his dedication to advancing medical science and improving therapeutic options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…